Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HAT
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
HAT Therapeutics is a biotechnology company focused on developing first-in-class small molecule activators of Histone Acetyltransferases (HATs) to treat neurodegenerative diseases. The company's lead programs target the restoration of epigenetic balance and synaptic plasticity, which are often impaired in conditions like Alzheimer's disease. By utilizing a proprietary platform to identify potent and selective HAT activators, the company aims to provide disease-modifying therapies that can improve cognitive function and memory. HAT Therapeutics is currently in the pre-clinical stage, advancing its pipeline toward IND-enabling studies.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on HAT.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAT.